SCHEMBL15100747

SCHEMBL15100747

C/N=C(\N)N(C)C(=N)N(C)c1ccc(O)c(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
RGS12 O14924 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
MAPK1 P28482 1/20 0.42
BRCA1 P38398 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
GNAI1 P63096 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14868433 0.84 ALOX15 (0.43) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL14868412 0.75 KDM4E (0.41) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL14868383 0.70 ALOX15 (0.42) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL11271935 0.68 KDM4E (0.44) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL22373636 0.66 LMNA (0.37)
SCHEMBL31572011 0.65 TDP1 (0.55) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL11793624 0.64 SMN1; SMN2 (0.55) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL25540950 0.64 ALDH1A1 (0.59) KDM4EMEN1RGS12USP2ALDH1A1
SCHEMBL14868431 0.62 ALOX15 (0.41) KDM4EMEN1RGS12USP2ALDH1A1
Metformin Xr SCHEMBL4210659 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013103384-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS ELCELYX THERAPEUTICS, INC. (US) 2013-07-11 WO disclosed